Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
155 hedge funds and large institutions have $522M invested in Progenics Pharmaceuticals Inc in 2018 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 57 increasing their positions, 38 reducing their positions, and 16 closing their positions.
160% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $5.48M
50% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 38
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
9% more capital invested
Capital invested by funds: $478M → $522M (+$43.2M)
2% more funds holding
Funds holding: 152 → 155 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$20.2M |
| 2 |
BlackRock
New York
|
+$10.7M |
| 3 |
Morgan Stanley
New York
|
+$4.78M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$24.4M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$10.1M |
| 3 |
PA
Pinnacle Associates
New York
|
-$2.39M |
| 4 |
JP Morgan Chase
New York
|
-$2.38M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$1.31M |
PGNX Hedge Fund Activity: Q2 2018 in Review
155 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2018, worth a combined $522M — up 9% from $478M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PGNX positions and 16 closed out — a net gain of 3 holders — while 57 added to existing stakes and 38 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $20.2M. The largest seller was Federated Hermes, cutting an estimated $24.4M.
- 155 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2018, up from 152 in Q1 2018.
- Funds reported $522M of Progenics Pharmaceuticals Inc stock for Q2 2018, up 9% quarter-over-quarter.
- 19 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2018 and 16 closed out, a net change of +3 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q2 2018 was Farallon Capital Management, an estimated $20.2M added.
- The largest Progenics Pharmaceuticals Inc seller in Q2 2018 was Federated Hermes, an estimated $24.4M sold.
Based on aggregated 13F filings for Q2 2018.